CG Oncology, Inc. Operating Income
CG Oncology, Inc. (CGON) reported Operating Income of -$86.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- CG Oncology, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$86.40M.
- CG Oncology, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$66.39M.
- CG Oncology, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$48.70M.
- CG Oncology, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$51.13M.
- CG Oncology, Inc. operating income (loss) for fiscal 2025 was -$190.77M.
- CG Oncology, Inc. operating income (loss) for fiscal 2024 was -$114.67M.
- CG Oncology, Inc. operating income (loss) for fiscal 2023 was -$55.45M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$86.40M 10-Q · filed 2026-08-06 | -$152.79M 10-Q · filed 2026-08-06 | -$201.49M derived: sum of 3 quarters · filed 2026-08-06 | -$252.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$66.39M 10-Q · filed 2026-05-08 | -$115.09M derived: sum of 2 quarters · filed 2026-05-08 | -$166.22M derived: sum of 3 quarters · filed 2026-05-08 | -$214.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$48.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$99.83M derived: sum of 2 quarters · filed 2026-02-27 | -$148.57M derived: sum of 3 quarters · filed 2026-08-06 | -$190.77M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$51.13M 10-Q · filed 2025-11-14 | -$99.87M derived: sum of 2 quarters · filed 2026-08-06 | -$142.07M 10-Q · filed 2025-11-14 | -$180.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$48.74M 10-Q · filed 2026-08-06 | -$90.94M 10-Q · filed 2026-08-06 | -$128.99M derived: sum of 3 quarters · filed 2026-08-06 | -$157.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$42.20M 10-Q · filed 2026-05-08 | -$80.25M derived: sum of 2 quarters · filed 2026-05-08 | -$108.55M derived: sum of 3 quarters · filed 2026-05-08 | -$134.40M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$38.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$66.34M derived: sum of 2 quarters · filed 2026-02-27 | -$92.20M derived: sum of 3 quarters · filed 2026-02-27 | -$114.67M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$28.30M 10-Q · filed 2025-11-14 | -$54.15M derived: sum of 2 quarters · filed 2025-11-14 | -$76.62M 10-Q · filed 2025-11-14 | -$95.97M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$25.85M 10-Q · filed 2025-08-08 | -$48.32M 10-Q · filed 2025-08-08 | -$67.68M derived: sum of 3 quarters · filed 2026-02-27 | -$81.72M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$22.47M 10-Q · filed 2025-05-13 | -$41.82M derived: sum of 2 quarters · filed 2026-02-27 | -$55.87M derived: sum of 3 quarters · filed 2026-02-27 | -$68.19M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$19.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$33.40M derived: sum of 2 quarters · filed 2026-02-27 | -$45.72M derived: sum of 3 quarters · filed 2026-02-27 | -$55.45M 10-K · filed 2026-02-27 |
| 2023-09-30 | -$14.04M 10-Q · filed 2024-11-12 | -$26.37M derived: sum of 2 quarters · filed 2024-11-12 | -$36.09M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$12.33M 10-Q · filed 2024-08-08 | -$22.05M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$9.72M 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |